Try The Farmer's Dog fresh dog food for 50% off with this National Pet Day deal 🐾
Try The Farmer's Dog fresh dog food for 50% off with this National Pet Day deal 🐾 Get 50% off your first delivery of any recipe and plan from The Farmer's Dog.
You can find some of the best National Pet Day deals right now to help you treat your pup to something tasty and keep a few extra bucks in your pocket.
The Farmer's Dog is offering new customers 50% off their first order of any recipe and plan for any dog type. The fresh dog food delivery service is known for its vet-developed meal plans that are made using human-grade ingredients and customized for your dog's specific needs and preferences. If you've been considering trying out fresh dog food delivery services, I suggest checking out The Farmer's Dog this April!
📲 Follow us: Check out USA TODAY Shopping on Instagram for deals, trends and more
How much does The Farmer's Dog cost?
The vet-developed meal plans are formulated with fresh, human-grade ingredients so your furry friends can eat healthy for years to come. The refrigerated deliveries are flexible based on your schedule and feature eco-friendly packaging. Meal plans range from about $2 to $12 per day and delivery options range from one week to three months of food and include free shipping.
When I tried The Farmer's Dog, two weeks worth of meals for my two dogs, Rufio and Ace, would have been $119.30. With today's pet deal, you could save 50% on the first box.
🦴 How does The Farmer's Dog work?
To get started with The Farmer's Dog, you'll take a short quiz about how many dogs you have, breed, age, weight, dietary restrictions, activity levels and diet history. After you complete the quiz, The Farmer's Dog will determine the appropriate meal plan with recommended recipes and weekly pricing. Your pup's meals will be formulated with USDA human-grade fresh ingredients and packaged into pre-portioned packs so all you have to do is open and pour.
🐶 New Chewy shopper? Get a $20 eGift card and free shipping with your first order of $49 or more
🛍️ USA TODAY Shopping: Sign up for our weekly newsletter to get the best shopping delivered to your inbox
Is The Farmer's Dog worth it?
If you're thinking about giving your dog a delicious new diet, The Farmer's Dog is absolutely worth a try. When I tried the brand out for my two dogs, we (the dogs) loved it. Both my dogs gobbled up the food on a daily basis, it seemed to improve their digestion and the transition period was very mild.
The cost of The Farmer's Dog was comparable to our usual dry dog food, so as long as you have the freezer space, I highly recommend trying out The Farmer's Dog.
Shop The Farmer's Dog deal
Dental hygiene tips for dogs and cats
Avoid expensive visits to the vet by taking care of your pets' dental hygiene.
Problem Solved
When is National Pet Day 2025?
National Pet Day 2025 is on Friday, April 11. The holiday is celebrated annually on April 11.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Does This News Make Meta Platforms Stock a Buy?
Meta Platforms is taking steps to improve its advertising process with AI. It could make an already highly profitable business even more so. There are other reasons to buy the stock. 10 stocks we like better than Meta Platforms › Several years ago, Facebook parent Meta Platforms (NASDAQ: META) changed its name, partly to reflect its newfound focus on its metaverse ambitions. Although the company is still working on that project, its initiatives in artificial intelligence (AI) garnered more headlines recently. Meta is looking to transform its business through AI, and recent news suggests it may take a significant step in that direction by the end of 2026. Let's examine these developments and determine whether they make Meta Platforms stock a buy. Meta Platforms makes most of its money from advertising to its massive user base. As of the end of the first quarter, Meta boasted 3.43 billion daily active users across its websites and apps, which include Facebook, Instagram, Messenger, and WhatsApp. However, Meta's ad business could become even better if it could provide more value to advertisers by improving their ad creation and launch processes. It already started to do that with the use of AI-powered tools -- for instance, helping advertisers define their target audience using AI. While businesses typically need to conduct research to figure that out, AI is making the job faster, easier, and cheaper. However, Meta is looking to take the next steps. According to a report from The Wall Street Journal, it aims to automate the process with AI from start to finish. Businesses will be able to use the technology at every step of the way -- to create images, tweak them, generate appropriate text, define the target audience, and more. Meta Platforms aims to complete this by the end of next year. What does this mean for investors? If successful, Meta Platforms' new AI tools for ads could reduce advertising expenses for companies while they achieve similar (or perhaps even better) results. If that's the case, demand for Meta's AI-powered tools to post ads across its websites and apps would increase significantly, leading to even more impressive sales. To be clear, Meta's ad business would be a key growth driver anyway. The digital ad market is still growing, and the tech leader's deep ecosystem of users makes it a valuable target for business clients. However, these new initiatives would further enhance this already highly profitable offering. Meanwhile, Meta is also improving engagement thanks to AI. Its algorithms have helped increase the amount of time users spend on Facebook and Instagram, so the company is working on both sides of the commerce equation with AI. These efforts should pay off in the long run, especially considering it has other potential growth drivers. It has been ramping up commercial messaging on WhatsApp, as well as working on the metaverse. Now, Meta Platforms isn't without risk. U.S.-China trade tensions could impact its financial results. During the first quarter, it received less advertising revenue from Asia-based retailers after the Trump administration ended a loophole that allowed some imports from China to enter the U.S. tax-free. Still, despite this headwind, Meta Platforms' first-quarter results were excellent. Revenue increased by 16% year over year to $42.3 billion, while net earnings per share came in at $6.43, 37% higher than the year-ago period. There might be more uncertainty if the trade wars continue, but Meta Platforms is showing that it can perform reasonably well despite that. Some might also point to the company's valuation as a reason to avoid the stock. Meta's forward price-to-earnings (P/E) ratio is 27.4 as of this writing, much higher than the average of 19.1 for the communication services industry. But given the Facebook parent's excellent results and strong prospects, it seems worth a premium. In my view, Meta Platforms will more than justify its relatively steep valuation in five years or more, which still makes it a stock worth owning for a long time. Before you buy stock in Meta Platforms, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Meta Platforms wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Meta Platforms. The Motley Fool has positions in and recommends Meta Platforms. The Motley Fool has a disclosure policy. Does This News Make Meta Platforms Stock a Buy? was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Posts falsely claim low-cost carriers to introduce standing seats in 2026
"Standing seats in planes: A new reality of budget airlines beginning 2026," reads a Malay-language Facebook post on May 18, 2025. It describes the seats as "a cross between bicycle seats and a standing position" and claims they are being introduced to reduce cost and increase capacity. The post features three images of the vertical, saddle-like seats designed to allow passengers to sit in a semi-upright position. The false claims spread after British tabloid Daily Mail published an article titled "Is this the future of travel? Low cost airlines could launch standing only seats as early as next year" on May 21, 2025 (archived link). The report claims that the SkyRider standing chairs, made by aircraft seat manufacturer Aviointeriors, can increase passenger capacity by 20 percent. Similar posts were shared elsewhere on Facebook. But Aviointeriors clarified in an Instagram post on May 23 that the "standing seats" were merely prototypes dating back to 2012 (archived link). "Designed as a bold response to one of the aviation industry's most pressing challenges, while maximizing space and ergonomics it was never meant to be taken at face value," the company said. A check on Aviointeriors' website also shows the SkyRider standing seats are not part of the company's catalogue (archived link). When contacted by AFP, the EASA confirmed that it had not received applications to certify standing seats in commercial aircraft. "Such seats would pose significant technical challenges, particularly in terms of emergency evacuation," it told AFP, adding that the design of a plane's fuselage does not allow for passengers to stand near windows. "Any airline wishing to introduce this type of seat will face significant challenges, both in terms of aircraft reconfiguration and in demonstrating compliance with strict safety and evacuation requirements." Irish low-cost carrier Ryanair also told AFP that the airline was not considering introducing the seats. However, its head Michael O'Leary said in 2009 that he would not have any problem introducing standing seats on planes, but pointed out that such a move will likely be rejected by the European Union for safety reasons.
Yahoo
2 hours ago
- Yahoo
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
SAN CARLOS, Calif., June 11, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in New York City and via webcast on June 26, 2025 at 8:30 am ET. John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, along with the Company's leadership team and distinguished key opinion leaders, will provide an update on BeOne's extensive global innovation pipeline and platforms, including new assets, targets and clinical data, and will share insights on the Company's vision, differentiated capabilities, and value creation drivers. Live webcast of this event can be accessed from the investors section of the Company's website at To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans, commitments, aspirations and goals related to BeOne's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law. View source version on Contacts Investors: Liza Heapes+1 857-302-5663ir@ Media: Kyle Blankenship+1 667-351-5176media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
